AMLX vs HIMS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
AMLX · Amylyx Pharmaceuticals$29.50 ▲ 6.81%
HIMS · Hims & Hers Health$26.00 ▲ 8.06%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- AMLX +142.2%
- HIMS -36.7%
Head to head
| Metric | AMLX | HIMS |
|---|---|---|
| Price | $29.50 | $26.00 |
| Change today | ▲ 6.81% | ▲ 8.06% |
| Market cap | $3.79B | $6.07B |
| Return, 3 months | +30.1% | -18.2% |
| Return, year to date | +144.2% | -19.9% |
| Return, 1 year | +139.6% | -36.6% |
| P/E (TTM) | -20.6 | -40.6 |
| P/B | 5.0 | 18.7 |
| P/E percentile vs own 5y | 3rd | 24th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +38.2% |
| Net profit growth (YoY) | -4.8% | -303.0% |
| Gross margin | – | 68.4% |
| Operating margin | – | -6.0% |
| Net margin | – | -5.5% |
| Return on equity | -74.7% | -32.0% |
| Analyst target vs. price | +56.4% | +33.2% |
| Analyst buy share | 100% | 27% |
| RSI (14) | 54 | 44 |
| 30-day volatility | 49.1% | 74.5% |
| Max drawdown, 1 year | -33.6% | -69.9% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- HIMS is the largest of the group by market value.
- AMLX has returned the most over the past year.
- HIMS carries the lowest trailing P/E.
- AMLX has been the calmest stock over the last 30 days.